Welcome to our dedicated page for Barinthus Biotherapeutics plc. SEC filings (Ticker: BRNS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Barinthus Biotherapeutics plc.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Barinthus Biotherapeutics plc.'s regulatory disclosures and financial reporting.
Barinthus Biotherapeutics plc (BRNS) reports that Oxford Science Enterprises plc has amended its Schedule 13G to show it no longer beneficially owns any American Depositary Shares of Barinthus. Oxford Science Enterprises reports 0 shares beneficially owned, representing 0.0% of the class, with no voting or dispositive power over any shares.
Barinthus Biotherapeutics plc. (symbol: BRNS) is the issuer of record for a Form 4/A filing submitted to the SEC.
Barinthus Biotherapeutics plc (BRNS) filed a Form 25 to remove its American Depositary Shares from listing and registration under Section 12(b) of the Securities Exchange Act of 1934. The company states it has complied with the rules of its exchange and the requirements of 17 CFR 240.12d2-2(c) for a voluntary withdrawal.
Barinthus Biotherapeutics plc. (symbol: BRNS) is the issuer of record for a Form 4 filing submitted to the SEC.
Barinthus Biotherapeutics plc. (symbol: BRNS) is the issuer of record for a Form 4 filing submitted to the SEC.
Barinthus Biotherapeutics plc (BRNS) director Anne M. Phillips reported merger-related dispositions of Barinthus equity on September 9, 2026. Several employee share options to acquire Ordinary Shares, including options over 34,328 shares at $17.00 and 18,604 shares at $4.27, ceased to represent rights in Barinthus and were converted into options over common stock of the acquiring parent company under an Agreement and Plan of Merger. In addition, 3,000 Ordinary Shares were disposed of to Barinthus and each such share was converted into the right to receive 0.111 share of common stock of the parent. No Rule 10b5-1 trading plan is reported, and no remaining Barinthus derivative positions are listed.
Barinthus Biotherapeutics plc (BRNS) director Pierre A. Morgon reported several dispositions of securities on September 9, 2026, in connection with the closing of a merger under an Agreement and Plan of Merger. Barinthus became a direct wholly owned subsidiary of a new parent company at the merger’s effective time.
On that date, multiple share options to acquire Barinthus ordinary shares, with exercise prices ranging from $0.0001 to $17.00 per share and expiring between 2030 and 2035, were reported as dispositions to the issuer and converted into options over the parent company’s common stock on the same terms. In addition, 10,506 ordinary shares (which may be held as ADSs) were reported as disposed to the issuer as each Barinthus share was converted into the right to receive 0.111 shares of the parent company’s common stock. No Rule 10b5-1 trading plan is reported.
Barinthus Biotherapeutics plc (BRNS) reported that Chief Medical Officer Leon Hooftman’s equity awards in Barinthus were restructured on September 9, 2026 in connection with the closing of a previously agreed merger. Two options to acquire a total of 335,166 Ordinary Shares were disposed of to Barinthus and, under the merger terms, each such option ceased to represent a right to acquire Barinthus shares and was converted into an option over common stock of the acquiring parent company. In addition, 361,530 restricted share units and the related Ordinary Shares were reported as acquired and then disposed of at the same Effective Time, reflecting that these RSUs were automatically released and assumed as RSUs over the parent company’s common stock. No Rule 10b5-1 trading plan is reported.
Barinthus Biotherapeutics plc. (symbol: BRNS) is the issuer of record for a Form 4 filing submitted to the SEC. Hammacher Alex reported disposition transactions in this Form 4 filing.
Barinthus Biotherapeutics plc (BRNS) reports that director Alex Hammacher’s Barinthus equity awards and shares were restructured on September 9, 2026 in connection with the completion of a merger under an Agreement and Plan of Merger. Several option grants over Barinthus ordinary shares ceased to be rights over Barinthus stock and were converted into options over common stock of the new parent company, while 3,000 Barinthus ordinary shares were exchanged, with each Barinthus share converted into the right to receive 0.111 share of the parent’s common stock.
Barinthus Biotherapeutics plc. (symbol: BRNS) is the issuer of record for a Form 4 filing submitted to the SEC.